This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AC Immune, Ltd.
Drug Names(s): ACI-24
Description: ACI-24 is a liposome-based vaccine with tetra-palmitoylated amyloid beta 1-15 peptide.
ACI-24 has been developed from AC Immune’s SupraAntigen Platform and is designed to act as an active vaccine stimulating the patient's immune system to produce beta-sheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques. During preclinical development, the ACI-24 has shown high efficacy in vivo by memory restoration and plaque reduction. The vaccine is also characterized by a very high specificity due to generating a conformation-specific antibody response. The favorable safety profile of ACI-24 is underlined through the absence of local inflammation in relevant models as well as its T-cell independent mechanism shown in preclinical development.
Additional information available to subscribers only: